Levi & Korsinsky announces the commencement of a class action lawsuit in the USDC for the Western District of Washington, Seattle Division, on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) who purchased shares between June 4, 2016 and July 7, 2016.
The complaint alleges that Juno materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015. These omissions led Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death. Then, following the death of two other patients in June and July, the U.S. Food and Drug Administration issued a clinical hold on the study, and Juno disclosed the patients’ deaths.
If you suffered a loss in Juno you have until September 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.